{"Title":"Fireman B.V.","Industry":"PHARMACEUTICAL PREPARATIONS","Employees":"17","Founded":"","Address":"","Phone":"(+49) 3641 508180.","Web_address":"http://www.inflarx.com","Market_cup":"$351.2mil","Revenues":"$0.2 mil (last 12 months)","Net_income":"$-15.0 mil (last 12 months)","Symbol":"IFRX","Exchange":"NASDAQ","Shares":"6.7","Price_range":"$15.00 - $15.00","Est_volume":"$100.0 mil","Manager":"J.P. Morgan/ Leerink Partners/ BMO Capital Markets","CO_managers":"-","Exp_to_trade":"11/8/2017","Status":"","Quiet_period":"Available only to Subscribers","Lock_up_period":"Available only to Subscribers","Scoop_rate":"Available only to Subscribers","Rating_change":"Available only to Subscribers","Business":"We are a clinical-stage biopharmaceutical company focused on applying our proprietary anti-C5a technology to discover and develop first-in-class potent and specific inhibitors of the complement activation factor known as C5a. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Our lead product candidate, IFX-1, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings."}